drugset / Trial / NCT03767322

Effect of Allopurinol or Febuxostat to Prevent Contrast Induced Acute Kidney Injury (CI-AKI)

NCT03767322

RandomizedParallel-groupDouble-blindPrevention

Summary

A randomized, placebo-controlled, double-blind clinical trial of effect of allopurinol or febuxostat to prevent contrast induced acute kidney injury (CI-AKI)

Timeline

Start
2018-12-05
Primary completion
2019-10
Completion
2019-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Allopurinol Small molecule 300 mg
Comparator Febuxostat Small molecule 80 mg

Indications